Ann: Presentation - quarterly investor update, page-2

'US FDA clears IND filed by the University of Rochester (NY) for a phase 1c/2a clinical trial of PXS‐5505 in hepatocellular
carcinoma (HCC) patients. PXS‐5505 to be added to current chemotherapy standard of care as first line therapy in newly
diagnosed patients with unresectable HCC carcinoma'

'unresectable' add that to my vocab



Hold on tight!
Its going to be one interesting year...most impressive prospective Biotech by far
Commercially minded Gary! Shareholders are fortunate to have him!
Practical achievable commercial targets! Well done!
Speed and reach of network...incredible!
Impressive pipeline
Drug discovery team....WORLD CLASS!